Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable stocks to buy under $20. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), announced on October 20 that it entered into a license agreement with Prestige Biopharma for “the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin” across a majority of European markets. Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge F ...

Core Insights - Teva Pharmaceuticals has entered into a license agreement with Prestige Biopharma for the commercialization of Tuznue, a biosimilar to Herceptin, in most European markets [1][8] - Tuznue is approved for treating breast cancer and metastatic gastric cancer, with marketing authorization granted by the European Commission in September 2024 [2][8] - The partnership leverages Teva's extensive commercial network and expertise in biosimilars, while Prestige Biopharma will handle production and supply [3][4] Company Overview - Teva Pharmaceutical Industries Ltd. is a leading biopharmaceutical company with over 120 years of experience, focusing on innovative medicines, generics, and biosimilars [6] - Prestige Biopharma, established in 2015, has a diversified portfolio and a GMP-certified manufacturing facility in Korea, with ongoing clinical development of key biosimilars [7]